For CML variants with high levels of SHH or BCL-2, the application of Venetoclax could be a relevant therapeutic option as it is a highly selective BCL-2 inhibitor that also has SMO-inhibiting properties (Figure 2) [64,65,66]. The gene discussed is SHH; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.